Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL therapy for r/r gynecologic tumors
NCT04766320Phase 1Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in gynecologic cancer, sponsored by Shanghai Tenth People's Hospital. Primary endpoint: Incidence of Serious Adverse Events at 12 months. Started Jan 2021; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
gynecologic cancer
Beyond the preview
Go deeper on NCT04766320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04766320.